Allogene Therapeutics Inc. to Report First Quarter 2025 Financial Results

South San Francisco, Calif., May 6, 2025 — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company specializing in allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapy for blood cancers and solid tumors, announced it will report its first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. This announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

The company, headquartered in South San Francisco, is focused on developing innovative therapies to treat cancer and autoimmune diseases. The upcoming financial results and business update are expected to provide insights into the company’s performance and strategic direction.

Conference Call and Webcast Details

The live audio webcast will be accessible on Allogene Therapeutics’ website under the Investors tab in the News and Events section. A replay of the webcast will be available for approximately 30 days following the event. For those interested in participating in the conference call and asking questions, registration is required. Participants will receive a personal PIN to access the call upon registration.

Company Overview

Allogene Therapeutics operates primarily out of its South San Francisco facility and serves patients in California. The company is listed on the Nasdaq stock exchange and has a market capitalization of approximately $369.61 million as of May 4, 2025. The stock closed at $1.62 on the same date, with a 52-week high of $3.78 on February 18, 2025, and a 52-week low of $1.23 on April 8, 2025. The price-to-earnings ratio stands at -1.27, reflecting the company’s current financial metrics.

For more information about Allogene Therapeutics and its mission, visit www.allogene.com .